AbCellera Biologics Inc. - 8-K Filing
AbCellera reports Q3 2026 revenue of $10.6M and net loss of $40.8M while expanding liquidity to over $890M following a $200M capital raise. (Items: 2.02 Results of Operations and Financial ConditionOn November 9, 2026, AbCellera Biologics Inc, 7.01 Regulation FDIn connection with its earnings call on November 9, 2026, to discuss its results for the quarter ended September 30, 2026, the C, 9.01 Financial Statements and Exhibits(d)ExhibitsExhibitNo)
Tickers: $ABCL
Read the full article at SEC EDGAR
Part of the story National CineMedia, Inc. - 8-K Filing (9 articles)